Alligator Bioscience presents updated data from the OPTIMIZE-1 study with the CD40 agonist mitazalimab vid ESMO Gastrointestinal Cancers Congress July 2–5 in Barcelona. Patients with metastatic pancreatic cancer treated with 900 μg/kg mitazalimab showed a median survival of 14,9 months and a two-year survival of 29,4 percent. The response rate was 54,4 percent for the higher dose compared to 22,7 percent for 450 μg/kg. The FDA has confirmed 900 μg/kg as the recommended dose for phase III.
|
Published July 1, 2025
Alligator presents 24-month data from OPTIMIZE-1
Notes
Johnson & Johnson acquires Halda Therapeutics for $3 billion
Magle Group submits application for EmboCept S
Quia Pharma is delisted from Nasdaq
Stenocare acquires CannGros
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
Sofinnova Partners raises EUR 650 million in new fund
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account